MARLBOROUGH, Mass.,
Oct. 10, 2016 /PRNewswire/
-- Boston Scientific Corporation (NYSE: BSX) announced today
that Professor Ian Meredith AM will
join the company as executive vice president and global chief
medical officer in January 2017. In
his new position, Professor Meredith will lead clinical and medical
affairs across Boston Scientific and will provide global leadership
of the company's clinical trial strategy.
Professor Meredith will succeed Executive Vice President and
Global Chief Medical Officer Keith
Dawkins, M.D., who has announced his intention to retire
from the company in January 2017.
"Ian is one of the world's leading cardiac device clinical
investigators and he has been an advisor to Boston Scientific for
many years," said Mike Mahoney,
chairman and chief executive officer, Boston Scientific. "His
strong relationships within the global research and clinical
community and his track record applying novel technologies to
advance science and care for patients make him ideally suited to
drive innovation and succeed Keith in this role. We are delighted
that he will be joining our team."
"We thank Keith for his many contributions to Boston Scientific
during the last nine years. His deep clinical, medical and
strategic expertise and advocacy for the patient will have lasting
influence within our company," said Mahoney.
Professor Meredith currently serves as professor of Medicine and
Cardiology for Monash University, Director of MonashHeart and
Monash Health and as executive director of the Monash
Cardiovascular Research Centre in Melbourne, Australia. He brings to Boston
Scientific more than 25 years of experience as a clinical and
interventional cardiologist. He has performed more than 10,000
invasive cardiac and coronary procedures, published more than 300
manuscripts and has been chief or principal investigator on 30
major international multi-center trials, including first-in-man
trials of new drug-eluting stents. Professor Meredith's work has
focused on the development and clinical evaluation of devices for
the treatment of coronary artery and structural heart disease, and
he has been at the forefront of emerging percutaneous cardiac valve
therapies. He was also the global principal investigator for the
Boston Scientific Lotus™ Valve REPRISE research program.
"Boston Scientific has demonstrated a commitment to delivering
meaningful innovation and I look forward to joining the team to
further develop the technology pipeline and deliver solutions
for patients worldwide," said Professor Meredith.
Professor Meredith received undergraduate and doctorate degrees
from Monash University in Melbourne,
Australia. He trained in Melbourne and completed his Ph.D. at the Baker
Institute before spending three years at the Brigham & Women's
Hospital and Harvard Medical School in
Boston.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for more than 35 years, we advance science for life by
providing a broad range of high performance solutions that address
unmet patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect on Twitter
and Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements are
based on our beliefs, assumptions and estimates using information
available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements
include, among other things, statements regarding our business
plans and personnel moves. If our underlying assumptions turn
out to be incorrect, or if certain risks or uncertainties
materialize, actual results could vary materially from the
expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases, have
affected and in the future (together with other factors) could
affect our ability to implement our business strategy and may cause
actual results to differ materially from those contemplated by the
statements expressed in this press release. As a result, readers
are cautioned not to place undue reliance on any of our
forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All of
these factors are difficult or impossible to predict accurately and
many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties
that may affect our future operations, see Part I, Item 1A
– Risk Factors in our most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, which
we may update in Part II, Item 1A – Risk
Factors in Quarterly Reports on Form 10-Q we have filed or
will file hereafter. We disclaim any intention or obligation to
publicly update or revise any forward-looking statements to reflect
any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.
CONTACT:
|
|
Media:
|
Tom
Keppeler
|
|
508-683-6585
(office)
|
|
Media
Relations
|
|
Boston Scientific
Corporation
|
|
tom.keppeler@bsci.com
|
|
|
Investors:
|
Susie Lisa
|
|
508-683-6585
(office)
|
|
Investor
Relations
|
|
Boston Scientific
Corporation
|
|
investor_relations@bsci.com
|
Logo - http://photos.prnewswire.com/prnh/20160203/329537LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/professor-ian-meredith-to-join-boston-scientific-as-executive-vice-president-and-global-chief-medical-officer-300341631.html
SOURCE Boston Scientific Corporation